CninMed – China Innovative Drugs Update

Announced Date: 2025-01-02 (January 2, 2025) Asset Name: IBI3009 Licensor: Innovent (Innovent Biologics, Inc.，China) Licensee (Buyer): … [China BD 2025] Innovent and Roche enters a 1 billion USD license on DLL3 ADC IBI3009Read more

Announced Date: 2024-12-23 (December 23, 2024) Asset Name: JYB1904 (RPT904) Licensor (Seller): Shanghai Jemincare Pharmaceutical (China) … [China BD 2024] Jemincare and RAPT Therapeutics Enters a 708 million USD License for anti-IgE Monoclonal Antibody JYB1904 (RPT904)Read more

Announced Date: 2024-12-18 (December 18, 2024) Asset Name: HS-10535 Licensor: Hansoh Pharma  (China) Licensee (Buyer):  MSD … [China BD deal 2024]Hansoh and MSD enters a 2 billion USD license on GLP-1Ra HS-10535Read more

Announced Date: 2024-11-18 (November 18, 2024) Asset Name: Licensor: VelaVigo Bio (China) Licensee (Buyer): Avenzo Therapeutics … [China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4/TROP2 BsADC ProgramRead more

Announced Date: 2024-11-14 (November 14, 2024) Asset Name: LM-299 Licensor: LaNova Medicines Ltd. (LaNova) (China) Licensee … [China BD 2024] LaNova and MSD Enters a 3.3 billion USD License on PD-1/VEGF BsAbs LM-299Read more

Announced Date: 2024-11-12 (November 12, 2024) Asset Name: HEC88473 (APL-18881) Licensor: Sunshine Lake Pharma (member of … [China BD 2024] Sunshine Lake (HEC) and Apollo  enters a 938 million USD License on FGF21/GLP-1 Bi-specific Fusion Protein HEC88473 (APL-18881)Read more

Announced Date: 2024-9-30 (September 30, 2024) Asset Name: RGT-419B(GDC-4198) and RGT-587(GDC-0587) Licensor: Regor Pharmaceuticals (China) Licensee (Buyer): … [China BD 2024] Regor and Genentech (Roche) enters a license on two CDK inhibitor programsRead more

Announced Date: 2024-10-16 (October 16, 2024) Asset Name: Undisclosed Licensor (Seller): Chengdu Baiyu Pharmaceutical  (China) Licensee … [China BD 2024] Chengdu Baiyu and Novartis enters a 1.17 billion USD license on small molecule anti-tumor assetRead more

Announced Date: 2024-10-29 (October 29, 2024) Asset Name: CMG1A46 Licensor: Chimagen Biosciences  (China) Licensee (Buyer): GSK … [China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46Read more